plasmonic assay
Recently Published Documents


TOTAL DOCUMENTS

19
(FIVE YEARS 6)

H-INDEX

6
(FIVE YEARS 2)

2021 ◽  
pp. 113584
Author(s):  
Mamata Karmacharya ◽  
Sumit Kumar ◽  
Chaeeun Lee ◽  
Yoon-Kyoung Cho
Keyword(s):  

2020 ◽  
Vol 1139 ◽  
pp. 111-118
Author(s):  
Priya V. Dukes ◽  
Pietro Strobbia ◽  
Hoan T. Ngo ◽  
Ren A. Odion ◽  
Daniel Rocke ◽  
...  

The Analyst ◽  
2020 ◽  
Vol 145 (14) ◽  
pp. 4950-4956
Author(s):  
ReJeana Cary ◽  
Sarah Unser ◽  
Ilaina Monroe ◽  
Joseph Holbrook ◽  
Laura Sagle

A simple, point-of-care plasmonic assay for copper detection in human plasma is developed.


ACS Sensors ◽  
2019 ◽  
Vol 4 (8) ◽  
pp. 2164-2172 ◽  
Author(s):  
Neus Jornet-Martínez ◽  
Lusine Hakobyan ◽  
Ana Isabel Argente-García ◽  
Carmen Molins-Legua ◽  
Pilar Campíns-Falcó

2019 ◽  
Vol 1051 ◽  
pp. 129-137 ◽  
Author(s):  
Flavio Della Pelle ◽  
Annalisa Scroccarello ◽  
Simona Scarano ◽  
Dario Compagnone

2017 ◽  
Vol 9 (391) ◽  
pp. eaal3226 ◽  
Author(s):  
Katherine S. Yang ◽  
Hyungsoon Im ◽  
Seonki Hong ◽  
Ilaria Pergolini ◽  
Andres Fernandez del Castillo ◽  
...  

Pancreatic ductal adenocarcinoma (PDAC) is usually detected late in the disease process. Clinical workup through imaging and tissue biopsies is often complex and expensive due to a paucity of reliable biomarkers. We used an advanced multiplexed plasmonic assay to analyze circulating tumor-derived extracellular vesicles (tEVs) in more than 100 clinical populations. Using EV-based protein marker profiling, we identified a signature of five markers (PDACEVsignature) for PDAC detection. In our prospective cohort, the accuracy for the PDACEVsignature was 84% [95% confidence interval (CI), 69 to 93%] but only 63 to 72% for single-marker screening. One of the best markers, GPC1 alone, had a sensitivity of 82% (CI, 60 to 95%) and a specificity of 52% (CI, 30 to 74%), whereas the PDACEVsignature showed a sensitivity of 86% (CI, 65 to 97%) and a specificity of 81% (CI, 58 to 95%). The PDACEVsignature of tEVs offered higher sensitivity, specificity, and accuracy than the existing serum marker (CA 19-9) or single–tEV marker analyses. This approach should improve the diagnosis of pancreatic cancer.


Sign in / Sign up

Export Citation Format

Share Document